Summary: The Centers for Medicare & Medicaid Services modified its coverage policy for Transcatheter Edge-to-Edge Repair (TEER) for mitral valve regurgitation, with an effective date of May 15, 2026. Here's what billing teams need to know before that date.
CMS TEER coverage policy changes carry real financial weight. Transcatheter edge-to-edge repair is a high-cost, high-complexity cardiac procedure — the kind where a single denied claim can mean tens of thousands of dollars in write-offs. This modified policy governs whether Medicare will pay for TEER in patients with mitral valve regurgitation, and the criteria shifts matter. The policy does not list specific CPT or HCPCS codes in the available data, so coordinate with your coding team to confirm the correct procedure codes for your charge capture before May 15, 2026.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Transcatheter Edge-to-Edge Repair (TEER) for Mitral Valve Regurgitation |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Interventional Cardiology, Cardiac Surgery, Structural Heart Programs, Hospital Outpatient Billing |
| Key Action | Review your TEER medical necessity documentation and prior authorization workflows before May 15, 2026 |
CMS TEER Coverage Criteria and Medical Necessity Requirements 2026
The real issue with TEER billing is that medical necessity documentation drives everything. CMS coverage for transcatheter edge-to-edge repair is not automatic — it has historically required detailed patient selection criteria, multidisciplinary heart team involvement, and specific anatomical and clinical thresholds. This modified coverage policy signals that CMS has updated those criteria. That means your current documentation templates may no longer be sufficient after May 15, 2026.
TEER for mitral valve regurgitation — the procedure using devices like MitraClip or PASCAL to clip the mitral valve leaflets together — sits at the intersection of high reimbursement and high scrutiny. CMS has paid close attention to patient selection since the National Coverage Determination framework for structural heart procedures was first established. Any modification to the coverage policy in this space typically reflects updated clinical evidence, new trial data, or a shift in how CMS defines which patients are appropriate candidates.
Because the specific policy text is not available in the current policy data, the exact revised criteria cannot be quoted here. What is clear is that this is a material modification — not a routine administrative update. Before May 15, 2026, pull the full policy document from CMS and compare it line by line against your current intake criteria. If you're not sure how the revised language maps to your patient population, loop in your compliance officer before the effective date.
What Medical Necessity Typically Requires for TEER Under Medicare
Historically, CMS TEER coverage policy has required documentation of several clinical factors for a claim to survive scrutiny. These have included:
| # | Covered Indication |
|---|---|
| 1 | Symptomatic mitral regurgitation — typically defined as severe (grade 3+ or 4+) primary or secondary MR, with documented symptoms despite optimal guideline-directed medical therapy |
| 2 | Surgical risk assessment — documentation that the patient is at prohibitive or high surgical risk for conventional mitral valve surgery, typically established by the multidisciplinary heart team |
| 3 | Heart team review — formal documentation that an interdisciplinary structural heart team evaluated the patient and determined TEER was appropriate |
| 4 | Anatomical suitability — echocardiographic evidence that the mitral valve anatomy is suitable for the clip-based repair technique |
| 5 | Facility requirements — TEER is typically covered only at hospitals that meet CMS structural heart program requirements, including volume thresholds and data registry participation |
These criteria reflect the historical framework. The modified policy may tighten, expand, or clarify any of these requirements. Do not assume the old criteria still apply in full after May 15, 2026. Read the updated policy text directly.
Prior Authorization and Coverage Policy Alignment
Whether TEER requires prior authorization depends on the Medicare Advantage plan or MAC jurisdiction. Traditional fee-for-service Medicare does not typically require prior authorization for TEER, but Medicare Advantage plans have their own prior auth requirements layered on top of the CMS coverage policy. If your structural heart program treats a significant volume of Medicare Advantage patients, confirm that your prior authorization submissions reference the updated coverage criteria after May 15, 2026.
A claim denial on a TEER procedure can run well into five figures. The reimbursement at stake makes documentation gaps extremely expensive. Do not treat this as a low-priority update.
CMS TEER Exclusions and Non-Covered Indications
CMS has historically excluded certain TEER applications from coverage. These exclusions reflect situations where the clinical evidence base has not met the coverage bar under Medicare's standard.
Pure primary MR in low-surgical-risk patients has generally not been a covered indication for TEER under CMS policy. These patients are considered appropriate candidates for conventional surgical repair or replacement, where outcomes data is stronger. Billing TEER for a low-surgical-risk patient without documented contraindications to surgery is a fast path to denial and potential overpayment liability.
TEER for indications outside mitral valve regurgitation — such as off-label use for mitral stenosis or other structural lesions — falls outside this coverage policy. CMS coverage policy is indication-specific. Submitting claims for procedures that don't match the covered indication, even with the correct procedure codes, creates claim denial risk and audit exposure.
Facilities that do not meet CMS structural heart program participation requirements may find their TEER claims non-covered regardless of patient selection. Registry participation — specifically the Society of Thoracic Surgeons/American College of Cardiology TVT Registry — has been a condition of coverage. Confirm your facility's registry status is current before May 15, 2026.
Coverage Indications at a Glance
Because the full revised policy text is not available in the current dataset, this table reflects the established CMS TEER coverage framework. Verify each indication against the updated policy before billing after May 15, 2026.
| Indication | Status | Notes |
|---|---|---|
| Severe symptomatic primary MR, high/prohibitive surgical risk | Covered (when criteria met) | Requires heart team documentation, anatomical suitability, registry enrollment |
| Severe symptomatic secondary (functional) MR on optimal GDMT | Covered (when criteria met) | Evidence base expanded post-COAPT trial; confirm updated criteria apply |
| Symptomatic MR, low surgical risk | Not Covered | Surgical repair/replacement is the appropriate treatment |
| TEER for mitral stenosis or non-MR indications | Not Covered | Outside scope of this coverage policy |
| TEER at non-participating or non-registry facilities | Not Covered | Facility must meet CMS structural heart program requirements |
| TEER without documented heart team evaluation | Not Covered | Heart team review is a condition of coverage, not a documentation preference |
CMS TEER Billing Guidelines and Action Items 2026
Transcatheter edge-to-edge repair billing is not forgiving. The procedure codes carry high RVUs, the reimbursement is significant, and CMS auditors know it. Here's what your team needs to do before May 15, 2026.
| # | Action Item |
|---|---|
| 1 | Pull the updated policy document now. Access the full modified policy at the CMS source before May 15, 2026. Read the revised criteria line by line. Do not rely on this post or any secondary summary as your primary reference for billing decisions. |
| 2 | Audit your documentation templates against the new criteria. Revise your pre-procedure documentation checklists, heart team attestation forms, and medical necessity letters to reflect whatever criteria the updated policy specifies. Documentation that was sufficient under the old policy may not meet the new standard. |
| 3 | Confirm your facility's registry participation status. TVT Registry participation has been a condition of CMS TEER coverage. Verify your data submission is current and your facility is in good standing before May 15, 2026. A lapsed registration can make an otherwise clean claim uncoverable. |
| 4 | Update your prior authorization workflows for Medicare Advantage. Even though traditional Medicare doesn't require prior auth for TEER, your Medicare Advantage contracts likely do. Ensure your prior auth requests reference the updated CMS coverage criteria after the effective date, not the old criteria language. |
| 5 | Brief your cardiology and cardiac surgery teams on the documentation requirements. Claim denial risk for TEER almost always traces back to incomplete clinical documentation, not coding errors. Your physicians need to know what CMS now requires in the chart — specifically around surgical risk assessment, heart team review, and anatomical suitability findings. |
| 6 | Flag any pending claims with dates of service near May 15, 2026. Claims straddling the effective date may need special handling. Procedures performed before May 15, 2026 should be billed under the prior criteria. Procedures on or after that date fall under the modified coverage policy. Don't mix criteria versions in your documentation. |
| 7 | Loop in your compliance officer if you're uncertain. TEER reimbursement is high enough that an audit liability here is not a theoretical risk. If your compliance officer hasn't reviewed the updated policy language by early May 2026, escalate it. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for TEER Under This CMS Policy
The available policy data does not include specific CPT, HCPCS, or ICD-10 codes. Do not rely on inferred or guessed codes for TEER billing.
For reference, TEER procedures have historically been reported using procedure-specific CPT codes that your coding team and cardiology service line should already have in your charge capture system. Confirm the exact codes with your cardiology coder or coding consultant, and verify they align with whatever code-level guidance appears in the full updated CMS policy document.
What to confirm with your coding team before May 15, 2026:
- The correct CPT code(s) for the TEER procedure itself, including any applicable add-on codes for imaging guidance
- The appropriate ICD-10-CM diagnosis codes for mitral regurgitation and related cardiac conditions that support medical necessity
- Whether any HCPCS device codes apply for the clip system used (MitraClip, PASCAL, or other FDA-approved devices)
- Any facility-level billing requirements that differ from the professional fee billing guidelines for this procedure
If the updated CMS policy document includes an explicit code list, make that your authoritative source. Do not use codes from third-party summaries — including this one — without cross-checking against the actual policy text.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.